Article Search

Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial

September 1, 2026

This is a practical, easy-to-adopt result. In 644 patients on highly emetogenic chemotherapy, all getting NEPA plus olanzapine, a single 6 mg day-1 dex dose or no dex at all was noninferior to the standard 4-day course (complete response 72%, 72%, and 70%), with clearly less insomnia, hiccups, anxiety, and reflux. The day-1-only arm is the sweet spot, since going fully dex-free cost some early nausea control over days 1 to 3 before catching up. Caveats: it was open-label, only 6% were on concurrent immunotherapy, and the high-dose cisplatin subgroup was small, but for most of our HEC patients, olanzapine plus one day of dex looks like plenty.

Read More »

Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer

September 1, 2026

This feels like the first real crack in the "undruggable" non-G12C RAS wall in lung cancer: a pan-RAS(ON) inhibitor with responses across G12D, G12V, and other alleles in patients who had already received platinum and immunotherapy. At the 160–220 mg range (the phase 3 dose is 200 mg), patients who hadn't yet received docetaxel had a 42% response rate, median progression-free survival (PFS) of 8 mos, and median overall survival (OS) of 16 mos, which looks well ahead of what we expect from docetaxel, though that's a cross-trial comparison. The catch is tolerability: about half had grade 3 or higher events, 9 in 10 got rash, and most got diarrhea, so rash prophylaxis and proactive GI management will matter just as it does on PDAC. The randomized RASolve 301 trial against docetaxel is the one to watch before this moves into practice.

Read More »

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma

September 1, 2026

This is a really encouraging look at chemo-free frontline therapy for symptomatic or high-burden FL and MZL. Eight cycles of mosunetuzumab alone produced a 71% complete response (CR) rate, escalation to pola-obinutuzumab for PET-positive patients pushed CR to 86%, and 2-year progression-free survival (PFS) was 89% with no maintenance. Toxicity was impressively outpatient-friendly: CRS was all grade 1, no one needed tocilizumab, and there was no immune effector cell–associated neurotoxicity syndrome (ICANS), though the shingles and HSV reactivations make a good case for antiviral prophylaxis. It's a small single-center study with two CD20-negative relapses to keep in mind, but the ctDNA–PET concordance hints at an MRD-guided "treat less when you can" future.

Read More »

Outbreak of Severe Methemoglobinemia during Maritime Migration

September 1, 2026

This is a fascinating toxicology detective story with real hematology lessons. Among 82 mostly young male migrants arriving in Lampedusa, median methemoglobin was 45% (43% were at 50% or higher), and the culprit was dermal absorption of N-methylaniline, a gasoline additive, from fuel-contaminated seawater pooling in the boats. Our takeaway is the delayed hemolysis: it hit most patients with available data around days 2 to 4 (up to day 7), every patient with transfusion data needed blood, 4 had splenic rupture, and G6PD deficiency turned up in 16 of 44 tested. It's a good reminder that antidotes only work if they are on the shelf.

Read More »

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma

September 1, 2026

These are very compelling phase 1 numbers in a heavily pretreated, all triple-class–refractory population. All 38 patients responded, 79% had a complete response, median progression-free survival (PFS) was 30 mos, and 3-year overall survival (OS) was 65%. The safety profile is the real headline: at the recommended dose there was no grade 3 or higher CRS, only one grade 3 immune effector cell–associated neurotoxicity syndrome (ICANS), and none of the delayed parkinsonism, cranial-nerve palsies, or colitis we’ve learned to watch for with cilta-cel. That said, it’s a small single-arm study, and the “cleaner binder” comparison to cilta-cel is in vitro and hypothesis-generating, so the iMMagine phase 2/3 data will tell us whether this truly earns a spot ahead of cilta-cel.

Read More »

Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal

September 1, 2026

This one could reshape post-polypectomy surveillance. In nearly 11,000 patients with high-risk adenomas, waiting 5 years instead of 3 for the first surveillance colonoscopy was noninferior for colorectal cancer incidence (under 1% in both arms), with no apparent shift toward later-stage disease and roughly half as many colonoscopies. The 3-year arm picked up more advanced adenomas (15% vs 11%), but that didn't translate into fewer or earlier cancers. Caveats: this is an interim analysis that only narrowly met noninferiority, and only about two-thirds of patients completed 5-year surveillance, so the 10-year data will be the real test before guidelines move.

Read More »

Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis

September 1, 2026

This is a large, well-designed negative trial. In more than 142,000 adults aged 50 to 77 in England, adding three annual rounds of the Galleri multicancer blood test to usual care did not reduce stage III/IV diagnoses across 12 prespecified cancers. There's an intriguing but non-significant trend toward fewer stage IV cancers, so longer follow-up is the real story to watch, and safety wasn't an issue (fewer than 1% had trial-related adverse events, none serious). For now this doesn't support routine MCED screening outside a trial, so have that conversation ready when patients ask about ordering it.

Read More »

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer

September 1, 2026

This 5-year update should settle the debate for many of us: in 261 patients receiving postoperative chemoradiation for high-risk head and neck squamous cell carcinoma (SCC), weekly cisplatin (40 mg/m²) stayed noninferior to 3-weekly 100 mg/m², and 5-year overall survival (OS) actually ran numerically higher (71% vs 59%), with less acute toxicity and no meaningful difference in late toxicity. Before anyone reads superiority into that, the 3-weekly arm carried more T4, N2–3, and hypopharyngeal disease, the noninferiority margin was generous, and the cohort was all Japanese, small, and treated before immunotherapy. For our postop patients, weekly cisplatin now looks like a fully defensible standard rather than a fallback for patients who can’t tolerate the bolus dose.

Read More »

SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer

September 1, 2026

This is another nail in the anti-TIGIT coffin. In more than 500 patients with untreated PD-L1–high non–small cell lung cancer (NSCLC), adding tiragolumab to atezolizumab missed both primary endpoints, and the numerical progression-free survival (PFS) and overall survival (OS) gains never reached significance. What it did add was toxicity: twice the grade 3–4 adverse events (AEs) and more discontinuations. Together with the other failed TIGIT programs, this pretty much closes the door on chemo-free anti-TIGIT combinations in first-line NSCLC, so single-agent PD-(L)1 or chemo-IO stays the standard for these patients.

Read More »

Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy

September 1, 2026

This looks like a real second-line win in relapsed small-cell lung cancer (SCLC): the B7-H3 ADC tambotatug pelitecan beat topotecan on every endpoint, with median overall survival (OS) of 13 vs 9 mos, median progression-free survival (PFS) of 7 vs 3 mos, and a 59% vs 10% response rate, plus a 32% vs 3% intracranial response rate. It was also easier to tolerate than topotecan, with grade 3 or higher events in 55% vs 78%, though the 5% rate of ILD/pneumonitis (mostly low grade) means we'll need the usual ADC vigilance. The caveats are that this is an interim, open-label analysis with only about 9 mos of follow-up in an all-Chinese population, and the OS sits right next to tarlatamab's 14 mos in DeLLphi-304, so the next debate will be about sequencing these two.

Read More »

Keyword Search

  • Article Search

  • Cancer Types

  • Month Contributed

  • Show FCS Articles Only

  • Sort Order

  • Number of Posts